Gene therapies for inherited skin disorders

Alya Abdul-Wahab, Waseem Qasim, John A. McGrath

研究成果: Article同行評審

22 引文 斯高帕斯(Scopus)

摘要

Skin is an amenable organ for gene replacement and gene editing therapeutics. Its accessibility makes it wellsuited for direct topical gene delivery, grafting of genetically corrected cells, and monitoring of possible adverse events. Monogenic recessive disorders with a clinically severe or life-threatening phenotype provide the best candidate diseases for the introduction of a single normal copy of the gene into the target cell, usually keratinocytes. Preclinical studies have shown impressive results in terms of gene correction using both in vivo and ex vivo approaches. The clinical application of gene replacement or genomic editing as potential therapies for inherited skin disorders, however, has been held back by the inadequacy of delivery vectors and concerns from regulatory agencies regarding safety; thus translation to clinical trials has been slow. Over the past 15 years, cell culture and animal models have shown efficient gene correction techniques as preludes to treat inherited skin disorders such as junctional epidermolysis bullosa, dystrophic epidermolysis bullosa, xeroderma pigmentosum, lamellar ichthyosis and Netherton syndrome, but so far only one patient has been treated in a clinical trial. This article reviews the current status of gene therapies for patients with inherited skin diseases and explores future perspectives.

原文English
頁(從 - 到)83-90
頁數8
期刊Seminars in Cutaneous Medicine and Surgery
33
發行號2
DOIs
出版狀態Published - 2014 6月 1

All Science Journal Classification (ASJC) codes

  • 手術
  • 皮膚科

指紋

深入研究「Gene therapies for inherited skin disorders」主題。共同形成了獨特的指紋。

引用此